Longboard Pharmaceuticals Q2 2024 Earnings Report $59.98 +0.02 (+0.03%) (As of 12/2/2024) Earnings HistoryForecast Longboard Pharmaceuticals EPS ResultsActual EPS-$0.56Consensus EPS -$0.46Beat/MissMissed by -$0.10One Year Ago EPS-$0.65Longboard Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALongboard Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/1/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseLBPH Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Wall Street Icon: “You must get on the right side of this thing” (Ad)I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Longboard Pharmaceuticals Earnings HeadlinesLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Receives $59.56 Average Price Target from AnalystsDecember 20 at 1:31 AM | americanbankingnews.comH. Lundbeck A/S (HLUN-A.CO)December 19 at 12:21 AM | finance.yahoo.comWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.December 22, 2024 | InvestorPlace (Ad)Longboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlookDecember 19 at 12:21 AM | investing.comLundbeck acquires all outstanding shares of Longboard PharmaDecember 5, 2024 | msn.comBright Minds initiated at outperform by Baird, Longboard takeover citedNovember 26, 2024 | msn.comSee More Longboard Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Longboard Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longboard Pharmaceuticals and other key companies, straight to your email. Email Address About Longboard PharmaceuticalsLongboard Pharmaceuticals (NASDAQ:LBPH), a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.View Longboard Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
